Johnson & Johnson Company's problems continueA group of anemia drugs widely used by cancer patients should be further restricted amid concerns they are used too aggressively and may be harmful, a U.S. panel of medical experts said on Thursday.
The Food and Drug Administration panel of outside experts also urged more study of the drugs -- Amgen Inc.'s (AMGN.O: Quote, Profile, Research Aranesp and Epogen and Johnson & Johnson's (JNJ.N: Quote, Profile, Research Procrit -- to help define their risks.
Story continued here.
Then, in yesterday's news we find this courtroom settlement story:
"We know that Johnson & Johnson knew they were misleading consumers and did nothing. It is clear the jury was outraged and wanted to punish Johnson & Johnson" -Dan Callister, with Squire Sanders & Dempsey, attorneys for the Sugar Association.
In other news, a recent infant death prompts another lawsuit against the Johnson & Johnson Company and one of their divisions Janssen-Ortho.
Regular readers of Clearing the Air know that our distrust of Johnson & Johnson and their political division, the Robert Wood Johnson Foundation, began when they dipped into the rent seeking cookie jar one time too many. That story can be found here, here, and here.